PT  - JOURNAL ARTICLE
AU  - TAKAYA SHIMURA
AU  - MIKA KITAGAWA
AU  - TOMONORI YAMADA
AU  - MASAHIDE EBI
AU  - TSUTOMU MIZOSHITA
AU  - SATOSHI TANIDA
AU  - HIROMI KATAOKA
AU  - TAKESHI KAMIYA
AU  - TAKASHI JOH
TI  - C-reactive Protein is a Potential Prognostic Factor for Metastatic Gastric Cancer
DP  - 2012 Feb 01
TA  - Anticancer Research
PG  - 491--496
VI  - 32
IP  - 2
4099  - http://ar.iiarjournals.org/content/32/2/491.short
4100  - http://ar.iiarjournals.org/content/32/2/491.full
SO  - Anticancer Res2012 Feb 01; 32
AB  - Background/Aim: C-reactive protein (CRP) has been associated with the development of many carcinomas, but the significance of CRP remains unclear for metastatic gastric cancer (MGC). Patients and Methods: Sixty one patients who received S-1 plus cisplatin for MGC were retrospectively identified and categorized into two groups depending on the serum CRP level before chemotherapy. Results: Overall survival was significantly shorter in the CRP≥1.0 group than in the CRP<1.0 group (median, 292 days versus 451 days; p=0.0004). Moreover, progression-free survival was significantly shorter in the CRP≥1.0 group than in the CRP<1.0 group (median, 115 days versus 188 days; p=0.0010). In a multivariate analysis, serum CRP level before chemotherapy was an independent prognostic factor for MGC (hazard ratio 4.20 [95% CI, 1.66 to 10.64] p=0.002). Conclusion: Serum CRP level before chemotherapy might be a potential prognostic factor for MGC.